Skip to main content

Refine your search

Text stickers on glass wall.

DrugTech Research Community Seminar

Multi-Step Domino Reactions: Facile Access to Bioactive Compounds for Life Sciences
  • Webinar
  • Health and well-being
Event date:
Time:
15:00–16:00
Event location:
Online
Additional information:
Zoom
Add to calendar:

Welcome to this seminar organized by the multi-disciplinary research community Drug Discovery and Delivery (DrugTech) at the University of Eastern Finland.

Prof. Dr. Svetlana B. Tsogoeva from the University of Erlangen-Nürnberg, Germany, will give a talk on Multi-Step Domino Reactions: Facile Access to Bioactive Compounds for Life Sciences.

Welcome and concluding remarks by Chairman, Professor Peter Wipf, School of Pharmacy, University of Eastern Finland. No registration required. 

Abstract:

A domino process is a powerful tool to economically and sustainably build up complex molecular architectures which drastically reduces the number of work-up and purification steps. Recently we developed new metal-free multi-step domino reactions and one-pot processes for the waste-reducing and cost-effective preparation of versatile frameworks, which otherwise are difficult to access via traditional methods. The developed new methods engage simple and readily available compounds in a wide range of domino reactions to construct e.g., azabicycles, highly functionalized anilines, quinazolines, and quinazoline-thiohydantoins of interest for medicinal chemistry. Very recently, we disclosed a versatile autocatalytic transamination metathesis reaction, which is a multi-step domino process. This novel methodology gives rapid and atom-economical access to N-substituted 1,4-dihydropyridines, which are privileged structures in bioactive compounds and pharmaceuticals.

The in vitro tests against multidrug‐resistant P. falciparum strains (Dd2 and K1), human cytomegalovirus (HCMV), and multidrug-resistant P glycoprotein-overexpressing CEM/ADR5000 leukemia cells revealed the selected domino products and some corresponding artemisinin-containing hybrid compounds as highly active agents, outperforming the clinical reference drugs. These recent results will be discussed in the talk.

Selected references:

1 F. E. Held, A. A. Guryev, T. Fröhlich, F. Hampel, A. Kahnt, C. Hutterer, M. Steingruber, A. Nesterov-Mueller, M. Marschall, S. B. Tsogoeva, Nature Commun., 2017, 8: 15071.

2 A. Çapcı, M. M. Lorion, H. Wang, N. Simon, M. Leidenberger, M. C. Borges Silva, D. R. M. Moreira, O. Friedrich, B. Kappes, J. Wang, L. Ackermann, S. B. Tsogoeva, Angew. Chem. Int. Ed., 2019, 58, 13066.

3 B. W. Grau, M. Dill, F. Hampel, A. Kahnt, N. Jux, S. B. Tsogoeva. Angew. Chem. Int. Ed., 2021, 60, 22307.

4 V. Klein, F. Schuster, S. B. Tsogoeva. Preprint: ChemRxiv. 2022, https://doi.org/10.26434/chemrxiv-2022-m6k1v.